Alnylam Pharmaceuticals reported $-35358000 in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 40.21M 12.43M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -35358000 6.24M Jun/2025
Amgen USD 1.57B 405M Jun/2025
Arrowhead Research USD -179089000 548.7M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Incyte USD 558.01M 323.82M Jun/2025
Ionis Pharmaceuticals USD 124M 271M Jun/2025
Moderna USD -818000000 146M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Novartis USD 4.53B 133M Jun/2025
PTC Therapeutics USD -71052000 1B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Sanofi USD 1.47B 855.43M Jun/2025
Sarepta Therapeutics USD 153.64M 537.16M Jun/2025
Takeda JPY 150.63B 257.93B Jun/2025
Tectonic Therapeutic USD -19010000 1.29M Jun/2025
Ultragenyx Pharmaceutical USD -114004000 35.77M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025
Xencor USD -31075000 17.19M Jun/2025